key: cord-0807392-0s11tdgd
authors: Hunter, Jennifer; Arentz, Susan; Goldenberg, Joshua; Yang, Guoyan; Beardsley, Jennifer; Mertz, Dominik; Stephen,
title: Rapid review protocol: zinc for the prevention or treatment of COVID-19 and other coronavirus-related respiratory tract infections
date: 2020-06-23
journal: Integr Med Res
DOI: 10.1016/j.imr.2020.100457
sha: 0122e410d1539f404a19761b90e37387be0a9617
doc_id: 807392
cord_uid: 0s11tdgd

Abstract Background . The global COVID-19 pandemic has prompted an urgent search for effective interventions. SARS-CoV-2 mortality/morbidity risk increases with age and for those chronic disease co-morbidities, both of which are associated with lower zinc status, as is the risk of infection. Methods Rapid review methods will be applied to a systematic review of zinc for the prevention or treatment of SARS-CoV-2 and viral respiratory tract infections in humans. Included are published studies reporting randomised and quasi-randomised controlled trials that compare zinc intervention to placebo and/or other comparator interventions. English and Chinese language databases will be searched for primary studies of viral respiratory tract infections and clinical trial registries for SARS-CoV-2 infections. Due to concerns about indirectness, studies evaluating non-SARS-CoV-2 coronavirus infections will be rated down by one level, and non-specific or confirmed non-coronavirus viral infections will be rated down by two levels. Review constraints include 1) using Google translate when screening articles published in languages other than English or Chinese and limited translation 2) following calibration, only one reviewer will screen articles, extract data, appraise quality and conduct the analysis, 3) prioritising data extraction and meta-analyses of SARS-CoV-2 studies and critical outcomes of other viral infections, followed by high risk groups and 4) reporting important preliminary findings prior to peer review if necessary. Discussion . The application of these rapid review methods and broadening the inclusion criteria to include other coronavirus-related viral respiratory tract infections aims to enable a timely evidence appraisal of priority research questions and dissemination of results.

both of which are associated with lower zinc status. [5] [6] [7] SARS-CoV-2 is a member of beta genus coronaviruses closely related to SARS-CoV. Currently, there is no specific antiviral treatment for SARS-CoV-2, nor for the other coronaviruses commonly associated with severe respiratory disease and mortality such as SARS-CoV and MERS-CoV.

Coronaviruses are responsible for up to 10% of upper respiratory tract infections. 8 Epidemiological surveillance suggests that coronavirus infections may be more common in adults and with coinfections. For instance, five-year surveillance data (2009) (2010) (2011) (2012) (2013) (2014) in China of adult and paediatric populations with acute respiratory tract infections identified a viral cause in 48.2% of cases. 9 Of the 18 viral pathogens screened for, coronaviruses (HCoV OC43, 229E, NL63, HKU1) were the fourth most common (4.66%, n=582/12,502) and were associated with the highest co-infection rate (47.07%, n=313/665). Adults were significantly more likely than children to be infected with coronavirus. Rates of coronavirus infection in other populations and countries have ranged from 2% to 10%. [10] [11] [12] [13] [14] [15] 

Zinc is a common nutritional supplement that is formulated as a stand-alone intervention or as a combination nutraceutical containing other vitamins, minerals and nutrient. Most zinc supplements are administered orally either as a single or divided dose, in the form of a lozenge, tablet, capsule or syrup. Some products are formulated for intramuscular or intravenous administration. The daily recommended dietary intake (RDI) of elemental zinc is around 2mg for infants up to 6 months of age and gradually increases to 11mg for males and 8mg for females older than 13 years. 16 Tolerable upper limits for zinc are estimated to be 7mg for children aged 1-3 years of age, increasing up to 25mg for adults and females of any age who are pregnant or lactating. The no observed adverse effect level (NOAEL) for adults is around 50 mg/day. 17

Through several mechanisms, zinc has the potential to reduce the risk of viral respiratory tract infections, including SARS-CoV-2, and shorten the duration and severity of illness. In vitro studies have demonstrated that zinc can inhibit the enzymatic activity and replication of SARS-CoV RNA polymerase and may inhibit angiotensin-converting enzyme 2 (ACE2) activity. [18] [19] [20] J o u r n a l P r e -p r o o f Zinc COVID-19 Rapid Review Protocol Zinc may also modify the host's response to an infection as it is an essential co-factor element with a broad range of functions in the body. Many of the beneficial effects of zinc appear to take place at the cell membrane. 8, 21, 22 Zinc (Zn2+) reduces the permeability of the cell membrane without penetration into or damage to the cell. Like other astringents, zinc alters the capillary epithelium, thus inhibiting transcapillary movement of plasma protein that in turn may reduce local oedema, inflammation, exudation, and mucus secretion. 21, 22 Zinc insufficiency/deficiency is known to diminish antibody and cell-mediated immunity in humans, is associated with an increased risk of infections, and may only become apparent upon immune system provocation. 23, 24 Zinc has an essential role in immune and airways function, wound healing and tissue repair that in turn, may delay or prevent recovery from viral respiratory illnesses. [25] [26] [27] [28] [29] [30] [31] Other consequences of zinc deficiency include an increased risk of vitamin A deficiency that is also critical for immune function, due to carrier proteins and activation enzymes being dependant on sufficient zinc status. 32

The potential role of zinc in preventing or treating SARS-CoV-2 infections is yet to be systematically evaluated and, along with other nutritional supplements, was not mentioned in a recent narrative review of TCIM for the treatment of coronavirus disease 2019 (COVID-19). 33 The findings of systematic reviews of related populations are promising; however, the reviews are limited by population, intervention, or are out of date. A 2016 Cochrane review that concluded zinc supplementation was effective for the prevention of pneumonia in children aged two to 59 months. 34 A 2017 systematic review of zinc lozenges found a 33% (95% CI: 21% to 45%) reduction in common cold duration compared to placebo. 35 The most recent 2013 Cochrane review of all types of zinc formulations for the common cold was later withdrawn due to methodological concerns that also applied to their earlier 2011 review, 36,37 leaving a 2000 review. 38 Also withdrawn from the Cochrane library is a 2017 protocol to update this review as it could not be completed within the editorial timeline. 39 Finally, zinc supplementation is not without potential safety concerns, that includes copper deficiency associated with higher doses and prolonged intake. 17

The primary objective of this rapid review is to assess the effects of zinc on the incidence, duration and severity of acute upper or lower respiratory tract infections caused by SARS-CoV-2 infection in people of any age and of any zinc status when used as a preventive supplement or as a therapy. The secondary objectives are to assess the effects of zinc on the incidence, duration and severity of acute upper or lower respiratory tract infections 1. caused by other coronavirus species, with a focus on SARS-CoV and MERS-CoV infections; 2. predominantly caused by viruses; and 3. in subgroups of populations at risk of zinc insufficiency/deficiency and those with a higher risk of severe acute respiratory syndrome (SARS) caused by SARS-CoV-2 infection.

A rapid review of primary studies with meta-analyses will commence at the end of April 2020 with the aim of completing the review by the end of June 2020. The rapid review methods applied were informed by leading methodologists, [40] [41] [42] [43] [44] including the most recent Interim Guidance from the Cochrane Rapid Reviews Methods Group, March 2020. 45 Review constraints include 1) using Google translate when screening articles published in languages other than English or Chinese and limited translation 2) following calibration, only one reviewer will screens articles, extract data, appraise quality and conduct the analysis, 3) prioritising data extraction and meta-analyses of SARS-CoV-2 studies, followed by other coronavirus infections and high risk groups and 4) reporting important preliminary findings prior to peer review if necessary.

This protocol was registered on 24 April 2020 with PROSPERO: CRD42020182044. 46 Minor edits have been made to improve the clarity of a priori registered statements. Other changes to the protocol are explicitly stated. This includes the decision to expand the inclusion criteria from only respiratory infections likely to be caused by a coronavirus to any viral infection and to tighten the exclusion criteria to respiratory illnesses that are almost always caused by a viral infection. All post-hoc changes will be reported with the published results.

Studies. Included are randomized controlled trials and quasi-randomised controlled trials. Excluded are systematic reviews, non-randomised studies of interventions and studies without a concurrent control, such as case series and case reports. conference abstract), with incomplete outcome data or published in languages other than English or Chinese will be included, however, the authors will not be contacted for further data nor clarification. Attempts will be made to translate studies published in languages other than English or Chinese, otherwise Google translate will be used to convert the text to English. Excluded are people with respiratory tract infections or other upper/lower respiratory illnesses when the cause is confirmed not to be a viral infection, or a non-viral cause is common. This includes adolescents and adults with pneumonia, people of any age with bronchitis and a concurrent underlying health problem /comorbidity, and people of any age with otitis externa/media infections. 47 People with epiglottis or croup-like symptoms are also excluded.

Studies of eligible and ineligible participants will be included; however, the certainty of the evidence will be downgraded due to indirect/nonexclusive treatment effects on coronaviruses. If separate data are available for the eligible populations, only this information will be extracted for analysis.

Intervention/exposure. Included are any zinc conjugates such as salts or amino-chelates, either as a single ingredient, in any form (e.g. tablet, syrup, lozenge, spray, liquid), dose and duration, administered via oral, intranasal, sublingual, transdermal, intramuscular or intravenous routes.

Excluded are co-interventions and zinc administered alongside other nutraceuticals, herbs or pharmaceuticals unless both the intervention and control groups receive the intervention. The exception are co-ingredients where the primary purpose is to increase zinc's absorption or cellular retention and co-ingredients are unlikely to have any additional therapeutic effects on respiratory viral infections (e.g. chloroquine 48 ). The a priori list of allowed co-ingredients are sulphur containing amino acids (e.g. histidine, methionine, cysteine, homocysteine, and taurine), low molecular weight J o u r n a l P r e -p r o o f Zinc COVID-19 Rapid Review Protocol acids (e.g. EDTA and citrate) and vitamin B12 (cobalamin, cyanocobalamin, methylcobalamin, adenosylcobalamin) for intestinal absorption of zinc, 49 and vitamin B6 (pyridoxine, pyridoxal, pyridoxamine and their 5´-phosphates) and magnesium for cellular retention of zinc. 50 Comparators/control. Included are no zinc supplementation, placebo, another nutraceutical or usual care active treatment, and dose comparators with no control group.

There are no limits on the setting (home, community or hospital), location, nor the country in which the study was conducted. Studies in which the formulation of zinc was adapted to ensure its prophylactic or treatment mechanisms of effect will be included, providing the zinc intervention was intended to prevent and/or treat mechanisms of respiratory viral disease. 51 Studies investigating zinc for prophylaxis or treatment on mechanisms not associated with respiratory viral infections are excluded.

Outcomes will not be used as a criterion for including nor excluding studies. 52 Studies reporting on at least one of the outcomes of interest rated as critically important or important, regardless of outcome priority in the primary study, may be included in the metaanalyses. The priority is to analyse critically important outcomes. If a study reports on other respiratory tract infection related outcomes that were not specified a priori as outcomes of interest for this review, the results will be noted in a narrative synthesis, but not necessarily pooled for metaanalyses nor reported in the summary of findings table.

As per the registered protocol, the outcome measures and their rating as critical, important and not important has been updated and informed by proposed core outcome sets for COVID-19 53,54 and other core outcome measures and sets published on the COMET Initiative database. 55,56 Any further changes will only be made prior to commencing the analysis and will be reported accordingly.

For studies evaluating the prevention of respiratory tract infections, the critical outcomes of interest are the incidence and frequency of respiratory tract infections, and all-cause mortality. Important outcomes are the duration of illness and progression to more severe illness.

For studies evaluating the treatment of respiratory tract infections, the critical outcomes are the duration of illness, symptom severity, progression to more severe illness and all-cause mortality. For all studies, important outcomes also include health related quality of life and adverse events.

The database search has been extended since protocol registration. Along with PubMed, selected Minor adjustment to search terms may be made if the title and abstract screen reveals too few or excessive results. Pre-specified terms will then be in/excluded to balance specificity and sensitivity of the search. Further details of the search strategy and terms are uploaded in a separate supplementary file.

Screening and data extraction. Review constraints include all reviewers screening the first 30-50 title/abstracts and 5-10 full papers for calibration and consistency, followed by only one experienced reviewer 44 independently screening the remaining titles/abstracts and full papers. To reduce the risk of missing eligible studies, a low threshold for inclusion will be applied to screening decisions and a second reviewer will check the studies excluded at full paper screen.

Additional constraints include: Any potentially eligible studies where there is insufficient information to include them in the review, including those awaiting translation into English, will be moved to the 'Studies Awaiting

Classification' table and noted in the PRISMA flow diagram.

EndNote 57 reference management software and electronic spreadsheets of piloted forms will be used for screening and data extraction. One reviewer will extract data about study design, participant number and characteristics, interventions, control/comparators, outcomes measures, effect size and direction.

Review constraints include all reviewers extracting 3-5 full papers for calibration and consistency, followed by data extraction by one reviewer only. For studies published in English, a second reviewer will check for errors. Attempts will be made to identify a second reviewer for studies published in languages other than English, otherwise Google translate will be used to convert the text to English.

Any discrepancies will be resolved by consensus.

The Cochrane RoB 2.0 tool, 58,59 will be used to appraise the risk of bias (RoB) of the outcomes in included studies that are critical outcomes of the review. For the remaining studies, the RoB 2.0 assessment will be applied to the study's primary outcome. Review constraints include all reviewers independently assessing the RoB of 3-5 studies for calibration and consistency, followed by only one reviewer assessing RoB for the remaining studies. For studies published in English, a second reviewer will verify the judgements and support statements. Attempts will be made to identify a second review for studies published in languages other than English. Any discrepancies will be resolved by consensus.

Measures of effect. It is expected that studies will use different measurement tools and time points.

Outcomes will be based on the number of participants, in preference to the number of events (e.g.

Zinc COVID-19 Rapid Review Protocol number of people with an infection or event rather than the number of infections or events admissions per person). Outcome measures will be ranked according to their objectivity, validity, reliability and responsiveness to change. If multiple instruments are used to measure the same construct, attempts will be made to transform alternative instrument scores to the most common reference instrument score in order to improve clinician interpretability and precision. 60 Time points will be grouped according to acute (less than 4 weeks), short-term (less than 3 months from randomisation or study enrolment), intermediate-term (more than 3 months but less than 1

year from randomisation or study enrolment), long-term (more than 1 year from randomisation or study enrolment), or not specified. Long-time points have greater importance for evaluating the prevention of illness; conversely, short-term time points are more important for evaluating the treatment of illness. The units of analyses in studies with multiple trial arms will be considered.

Decisions to pool or split data for analyses will be guided by published recommendations. 51 If a study reports repeated observations not amenable to time to event analysis, a maximum of two time points per study will be extracted to minimise unit-of-analysis error. These will be selected based on those most clinically important.

As per the registered protocol, the measures of effect have been edited so they are more specific and more closely reflect published research on core outcome sets for COVID-19. 53, 54 This includes only conducting a meta-analysis of critical outcomes rather than the previously stated maximum of 7 outcomes, and only reporting critical outcomes in the summary of findings table. Any further changes will only be made prior to starting the analysis and will be reported accordingly. Dichotomous outcomes will be presented as risk ratios (RR) in preference to odds ratios (OR). Timeto-event outcomes will be presented as hazard ratios (HR). Continuous data will be calculated as weighted mean differences (WMD) or standardized mean differences (SMD). Relevant 95% confidence intervals (CIs) will be calculated. The number needed to treat for additional benefit or harm (NNTB, NNTH) will be calculated as appropriate.

Review constraints may include excluding underpowered outcomes of interest from the metaanalyses if there are at least two adequately powered studies reporting the same outcome. 61 Also, the study authors will not be contacted for missing data. The potential impact of attrition bias/missing outcome data on the outcome of interest will be evaluated in domain 3 of the Cochrane Risk of Bias 2.0 tool. 58 Quantitative analysis. RevMan 5.3 62 and R software packages will be used for the meta-analyses.

Review constraints include limiting the analysis to critical outcomes (the exception will be SARS-CoV-2 infections) and one researcher entering the data and conducting a meta-analysis for an outcome, with verification from a second reviewer. Any discrepancies will be resolved by discussion until a consensus is achieved. Any subgroup analysis will be prioritised according to directness of evidence and relevance to at risk populations and limited to a maximum of 3 outcomes.

Clinical methodology and statistical heterogeneity will be considered in our decisions to pool studies. 63 Statistical heterogeneity will be assessed using the I² statistic, and homogeneity assessed with the chi² test. I² statistics will be interpreted according to guidelines from the Cochrane Handbook 51 (0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity). If statistical heterogeneity is identified, we will explore possible explanations using a priori subgroups (listed below under Subgroups).

If data of ten or more RCTs can be combined, a funnel plot will be created to explore the potential for small study effects (such as publication bias). Funnel plots will be visually inspected and statistically analysed using Egger's regression for continuous outcomes and the Harbord score for dichotomous outcomes. 64 The random-effects model will be used as it is assumed there will be clinical heterogeneity across the included studies. The inverse variance meta-analytic method will be used. Sensitivity analyses Missing data will not be imputed. The implications will be considered when appraising the risk of bias and interpreting the certainty of the evidence.

Sensitivity and subgroup analyses. Where possible, subgroup analysis of different zinc interventions according to dose, duration, formulation and administration and for the following discrete population groups will be conducted. We will use meta-regression to investigate dose effects. Data synthesis. The findings will be structured around the condition (e.g. pathogen, type/severity of illness), outcome measures (critical, important, other), risk of bias assessment for critical outcomes and primary study outcomes, characteristics of the intervention (dose, duration, formulation, administration etc), control (placebo or comparative intervention) and study characteristics (study design, participants, context, funding source). A summary of findings table will be limited to the critical outcomes and up to 3 critical or important outcomes for any subgroup analyses. Studies only reporting important outcomes will be narrated only. Other outcomes reported will be noted, however, the results will not be reported. Relevant results from clinical trials registries will be narrated.

Due to the urgency of disseminating evidence-based information, review findings will be reported as they become available and in the following order of priority, that begins with studies of populations with SARS-CoV-2 infection, followed by SARS-CoV and MERS-CoV infections, and then populations with higher risk of SARS-CoV-2 infections and/or increased morbidity/mortality. Dissemination may include the use of medRxiv.org for example, as "preprints" of review findings prior to formal peer review.

Zinc COVID-19 Rapid Review Protocol Rapid reviews respond to time and resource constraints that legitimately prevent the full application of the recommended methods for a high-quality systematic review. 45 Notwithstanding all efforts should be made to optimise the rigor, transparency and reproducibility of a rapid review, beginning with a protocol whenever possible. 45 

The decision to apply rapid review methods was made in response to a call from the World Naturopathic Federation (WNF) for researchers to quickly generate robust evidence summaries abour the potential role of commonly used naturopathic interventions. 85 The rapid review method constraints outlined in this protocol align with in the recently released Interim Guidance from the Cochrane Rapid Reviews Methods Group. 45 Constraints include not systematically searching the bibliography of all included articles, not contacting the authors for further information, using automated translation for studies published in languages other than English or Chinese, a single reviewer screening the majority of titles, abstracts and full-text articles, a single reviewer appraising the risk of bias and extracting data for analysis, and a staged approach, as needed, to the analysis and reporting of results. Steps have been implemented to optimise consistency and verify accuracy, as there are risks when only one reviewer screens, extracts and appraises the studies. 86 Other acceptable rapid review constraints that were not applied include the decision to conduct metaanalyses when possible, not to restrict the search by date or language, and to search more databases than the minimum three databases recommended by the Cochrane Rapid Reviews Methods Group SA is a naturopathic practitioner at an obstetrics and gynaecology clinic in Sydney, Australia. She has received payment for providing expert editing of naturopathic and herbal medicine educational programs, and for investigation of naturopathy, herbal medicines and nutraceuticals in clinical trials and spoken at workshops, seminars and conferences for which registration, travel and/or accommodation has been paid by the organisers.

JH is an Editorial Board Member of this journal. She is an academic general practitioner with a clinical interest in integrative medicine, has received payment for providing expert advice about traditional, complementary and integrative medicine, including nutraceuticals, to industry, government bodies and non-government organisations, and spoken at workshops, seminars and conferences for which registration, travel and/or accommodation has been paid for by the organisers.

GY is an academic researcher with interest in complementary and integrative medicine. She has spoken at research workshops, seminars and conferences for which registration and travel has been paid by the organisers.

JG is a naturopathic doctor at a functional bowel disease clinic in Colorado Springs, USA. He is also a research investigator at the Helfgott Research Institute, which is affiliated with a naturopathic medical school in Portland, USA. JG has spoken at research conferences for which registration, travel and/or accommodation has been paid by the organisers. As a medical research institute, Helfgott receives research grants and untied donations from foundations, universities, government agencies, individuals and industry. This review was not undertaken as part of a contractual relationship with any donor or sponsor.

JB is an independent professional librarian. DM is an infectious disease physician. SL is a clinical epidemiologist and respiratory physician. Stephen Leeder

Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19)

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Diabetes is a risk factor for the progression and prognosis of COVID-19

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Mineral intakes of elderly adult supplement and nonsupplement users in the third national health and nutrition examination survey

Prevalence of zinc deficiency and its clinical relevance among hospitalised elderly

Correlation between zinc status and immune function in the elderly

Efficacy of zinc against common cold viruses: an overview

New Epidemiological and Clinical Signatures of 18 Pathogens from Respiratory Tract Infections Based on a 5-Year Study

Epidemiological and clinical study of viral respiratory tract infections in children from Italy

Viral and Bacterial Etiology of Acute Febrile Respiratory Syndrome among Patients in Qinghai

Epidemiology and aetiology of influenza-like illness among households in metropolitan Vientiane, Lao PDR": A prospective, community-based cohort study

Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011-12 influenza season

Prevalence and seasonal distribution of respiratory viruses in patients with acute respiratory tract infections

Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012-2016)

Institute of Medicine Panel on Micronutrients

SCF/CS/NUT/UPPLEV/62 Final

Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition

Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

Zinc and respiratory tract infections: Perspectives for COVID-19 (Review)

How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action

Ion modulation of membrane permeability: effect of cations on intact cells and on cells and phospholipid bilayers treated with pore-forming agents

Reprogramming of the immune system during zinc deficiency

Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations

Zinc modulates cytokine-induced lung epithelial cell barrier permeability

Zinc modulates airway epithelium susceptibility to death receptormediated apoptosis

Apoptosis in the normal and inflamed airway epithelium: role of zinc in epithelial protection and procaspase-3 regulation

New insights into the role of zinc in the respiratory epithelium

Zinc metabolism in airway epithelium and airway inflammation: basic mechanisms and clinical targets. A review

Impact of zinc metabolism on innate immune function in the setting of sepsis

Zinc: mechanisms of host defense

Effect of zinc deficiency on hepatic enzymes regulating vitamin A status

Complementary, alternative and integrative medicine (CAM) for the treatment of Coronavirus disease 2019 (COVID-19): an overview: licensed under a Creative Commons Attribution 4.0 International License

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months

Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage

WITHDRAWN: Zinc for the common cold

Zinc for the common cold

Zinc for the common cold

Zinc for preventing and treating the common cold

AHRQ Methods: An Exploration of Methods and Context for the Production of Rapid Reviews. Research White Paper

Rapid reviews to strengthen health policy and systems: a practical guide.: World Health Organization, Alliance for Health Policy and Systems Research

Redefining rapid reviews: a flexible framework for restricted systematic reviews

Single screening versus conventional double screening for study selection in systematic reviews: a methodological systematic review

Protocol for a rapid review of zinc for the prevention or treatment of COVID-19 and other coronavirusrelated respiratory tract infections in humans. PROSPERO 2020 CRD42020182044. National Institute for Health Research

Importance of viruses in acute otitis media

Chloroquine is a zinc ionophore

Dietary factors influencing zinc absorption

Zinc content in tissues of pyridoxine deficient rats

Cochrane handbook for systematic reviews of interventions

Core Outcome Set for Clinical Trials of COVID-19 based on Traditional Chinese and Western Medicine

Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID)

RoB 2: a revised tool for assessing risk of bias in randomised trials

A revised tool for assessing risk of bias in randomized trials

Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability

Review Manager (RevMan). 5.3 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration

Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Serum zinc and pneumonia in nursing home elderly

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet

Serum zinc level and coronary heart disease events in patients with type 2 diabetes

Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India

Association of zinc deficiency and depression in the patients with end-stage renal disease on hemodialysis

The Coronavirus and the Risks to the Elderly in Long-Term Care

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Zinc in hair and serum of obese individuals in Taiwan

Zinc: the missing link in combating micronutrient malnutrition in developing countries

Effect of vegetarian diets on zinc status: a systematic review and meta-analysis of studies in humans

The nutrition CRSP: what is marginal malnutrition, and does it affect human function?

Plant breeding: a long-term strategy for the control of zinc deficiency in vulnerable populations

Dietary calcium, phytate, and zinc intakes and the calcium, phytate, and zinc molar ratios of the diets of a selected group of East African children

Effects of maternal zinc supplementation on pregnancy and lactation outcomes

Zinc deficiency in pregnancy and fetal-neonatal outcomes and impact of the supplements on pregnancy outcomes

Effect of gestational zinc deficiency on pregnancy outcomes: summary of observation studies and zinc supplementation trials

The dynamic link between the integrity of the immune system and zinc status

Zinc in health and chronic disease. The journal of nutrition

Alcoholism causes alveolar macrophage zinc deficiency and immune dysfunction

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial

Estimating Time to Conduct a Meta-analysis From Number of Citations Retrieved

Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence